

## **Running head: Coronary Heart Disease in SLE**

### **Association between Systemic Lupus Erythematosus and Coronary Heart Disease: a retrospective case-control analysis and Mendelian Randomization Study**

**Jinyun Chen<sup>1</sup>, Junmei Tian<sup>1</sup>, Wen Wang<sup>1</sup>, Shiliang Zhou<sup>1</sup>, Lu Zhang<sup>1</sup>, Wanlan Jiang<sup>1</sup>, Mingyuan Cai<sup>1</sup>, Peirong Zhang<sup>1</sup>, \*Ting Xu<sup>1</sup> & \*Min Wu<sup>1</sup>**

**Jinyun Chen**, M.D. & Ph.D., <sup>1</sup>Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [wing0087@163.com](mailto:wing0087@163.com);

**Junmei Tian**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [tjunmei@163.com](mailto:tjunmei@163.com);

**Wen Wang**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [972204148@qq.com](mailto:972204148@qq.com);

**Shiliang Zhou**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [zhoushiliang22@163.com](mailto:zhoushiliang22@163.com);

**Lu Zhang**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [luzhang2014@126.com](mailto:luzhang2014@126.com);

**Wanlan Jiang**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [jiang.wanlan@163.com](mailto:jiang.wanlan@163.com);

**Mingyuan Cai**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [caimingyuan0826@163.com](mailto:caimingyuan0826@163.com);

**Peirong Zhang**, M.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [zhpero@126.com](mailto:zhpero@126.com);

**Ting Xu**, M.D. & Ph.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail:

[daisy\\_tingting@163.com](mailto:daisy_tingting@163.com);

**Min Wu**, M.D. & Ph.D., Department of Rheumatology and Immunology, Third Affiliated Hospital of Soochow University, Changzhou 213000, China. E-mail: [wuumin807@sina.com](mailto:wuumin807@sina.com);

**Funding:** Supported by grants from the Science and Technology Project of Changzhou Health Committee for Young Talents (QN201805).

\* Correspondence and requests for materials should be addressed to T.X. (email:

[daisy\\_tingting@163.com](mailto:daisy_tingting@163.com)) or M.W. (email: [wuumin807@sina.com](mailto:wuumin807@sina.com)).

Word count: 2832

## Abstract

**Objectives** To appraise the causal effect of systemic lupus erythematosus (SLE) for risk of Coronary heart disease (CHD).

**Methods** We selected single nucleotide polymorphisms (SNPs) associated with SLE as instrumental variables (IVs) from three independent genome-wide association studies (GWAS), the three largest to date for SLE of European ancestry. Then we conducted two-sample Mendelian randomization (2SMR) analyses to estimate the effects of IVs on the odds of CHD and traditional coronary risk factors (including high LDL cholesterol levels, low HDL cholesterol levels, Apolipoprotein A-I, Apolipoprotein B, diabetes mellitus, and hypertension). Additionally, we searched for common risk loci between SLE and premature coronary atherosclerosis. Furthermore, we retrospectively reviewed the lipid profile of treatment-naïve SLE patients and age-matched healthy controls.

**Results** Genetically predicted SLE did not increase the odds of CHD. Nevertheless, we found mild causal relationships between SLE and decreased HDL cholesterol levels, and between SLE and decreased apolipoprotein A-I. There was one common risk locus (rs597808) between SLE and premature coronary atherosclerosis at a genome-wide significance level ( $P < 5 \times 10^{-8}$ ). Retrospective analysis showed decreased HDL-cholesterol ( $0.98 \pm 0.516$  mmol/L vs.  $1.46 \pm 0.307$  mmol/L in female,  $0.76 \pm 0.199$  mmol/L vs.  $1.19 \pm 0.257$  mmol/L in male; both  $P < 0.001$ ) and apolipoprotein A-I ( $1.06 \pm 0.314$  g/L vs.  $1.37 \pm 0.205$  g/L in female,  $0.87 \pm 0.174$  g/L vs.  $1.24 \pm 0.200$  g/L in male; both  $P < 0.001$ ) in naïve SLE patients.

**Conclusion** SLE may accelerate coronary atherosclerosis in young patients by reducing HDL cholesterol and apolipoprotein A-I intrinsically, but it seems not to play a predominant role in

CHD development in old patients.

**Keywords** systemic lupus erythematosus (SLE), Coronary heart disease (CHD), lipid profile, premature coronary atherosclerosis, two-sample Mendelian randomization study

## Introduction

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease with high heritability ( $\lambda_s=29$ ) [1]. Though long-term survival has increased with improved treatments, patients with SLE seem to have substantially increased risk for cardiovascular diseases, including coronary heart disease (CHD), which has been the leading cause of hospitalization and in-hospital mortality in patients with SLE [2–6]. Moreover, the risk of myocardial infarction in SLE patients was higher among Whites compared to Hispanics and Asians [7].

Traditional coronary risk factors such as age, high LDL cholesterol levels, low HDL cholesterol levels, cigarette smoking, diabetes mellitus, and hypertension may partially explain the increase in CHD [8]. Nevertheless, evidence demonstrating that SLE is an independent risk factor for CHD is growing [9–11]. However, most of the previous studies were retrospective observational researches based on small sample sizes, which would be strongly influenced by confounding factors, such as steroid usage. Unconfounded estimates of the causal relationship between SLE and CHD are therefore needed to understand the increased CHD risk in SLE patients.

As we know, SLE is a somewhat hereditary disorder [1, 12], and GWAS has found several risk loci (including SNPs) in SLE. Given that genetic variants are randomly assigned during meiosis according to Mendel's second law, Mendelian randomization (MR) that uses genetic variants as proxies for exposures to determine the causal relationship between an exposure and an outcome has been developed. We could think of it as a “natural” randomized controlled trial (RCT), which should reduce confounding. Our study aimed to assess the

causal relationship between SLE and CHD via MR analysis. In secondary analysis, we also assessed the causal relationship between SLE and traditional coronary risk factors. As patients with SLE were found to have premature coronary atherosclerosis, we also searched for common risk loci between SLE and premature coronary atherosclerosis. To confirm the results with real-world data, we retrospectively reviewed the lipid profile and the prevalence of CHD, diabetes mellitus and hypertension in treatment-naïve SLE patients.

## **Methods**

### **Study populations**

The MR analysis included three GWAS on SLE with summary-level data (Table 1). The study also included large sizes of participants enrolled in CARDIoGRAMplusC4D Consortium or CARDIoGRAM Consortium, two meta-analyses of GWAS on coronary heart disease for whom summary-level data were available (mean age>50 years old) [13, 14]. GWAS on hypertension, diabetes mellitus, LDL cholesterol levels, HDL cholesterol levels, apolipoprotein A-I, and apolipoprotein B were included as well. All of the participants were of European ancestry (except for CARDIoGRAMplusC4D Consortium, which was consisted of 92.85% European and 7.15% South Asian ancestry) and provided written informed consent in each of the contributing studies. We acquired summary data for all SNPs by our search from NHGRI-EBI GWAS catalog[15] or MR Base database [16]. The risk loci associated with premature coronary atherosclerosis were acquired from genome-wide scale time-to-event data analysis of UK Biobank data (282,871 British European ancestry samples) [17].

The real-world data were derived from treatment-naïve SLE patients who were still

followed-up in our hospital in the last two years and age-matched controls who had a health check in the same period. We retrospectively reviewed the lipid profile of SLE patients (n=218) and the healthy controls (n=95,132). The prevalence of CHD, diabetes mellitus and hypertension was evaluated in those SLE patients as well (Table 3).

**Table 1. Description of Contributing Studies**

<b>Contributing Studies (Consortium or Authors)</b>	<b>Sample Size (Cases/Controls)</b>	<b>Ancestry</b>
<b>GWAS for SLE</b>		
Bentham, J. et al.	23,210(7,219/15,991)	European
Langefeld, C.D. et al.	18,264(6,748/11,516)	European
Gateva, V. et al.	15,461(3,273/12,188)	European
<b>GWAS for CHD</b>		
CARDIoGRAMplusC4D	194,427(63,746/130,681)	92.85% European, 7.15% South Asian
CARDIoGRAM	86,995(22,233/64,762)	European
<b>GWAS for risk factors for CHD</b>		
Hypertension (MRC-IEU)	463,010(54,358/408,652)	European
Diabetes (MRC-IEU)	461,578(22,340/439,238)	European
HDL-cholesterol (Kettunen, J. et al.)	21,555	European
LDL-cholesterol (Kettunen, J. et al.)	21,559	European
Apolipoprotein A-I (Kettunen, J. et al.)	20,687	European
Apolipoprotein B (Kettunen, J. et al.)	20,690	European

## **Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

## **Instrumental variables**

We searched the GWAS catalog on March 8, 2020, to identify SNPs associated with SLE (using a  $P$ -value threshold of  $5 \times 10^{-8}$ ), and exclude those that were in significant linkage disequilibrium ( $r^2 > 0.3$ ). If a particular SNP is not present in the outcome dataset, an LD proxy would be used instead (within 250 kb and with a minimum  $r^2 = 0.8$ ). Using the remaining SNPs or LD proxies as independent instrumental variables (IVs), we applied 2-sample Mendelian randomization to estimate the effect of SLE on CHD or traditional coronary risk factors.

## **Statistical analysis**

Inference of causality in the estimated etiological associations between SLE and CHD or traditional coronary risk factors depends on the satisfaction of Mendelian randomization assumptions[18]: (1) the selected SNPs are associated with SLE; (2) the selected SNPs are not associated with confounders; and (3) the selected SNPs are associated with CHD or traditional coronary risk factors exclusively through their effect on SLE. If the above assumptions are satisfied, the selected SNPs are valid IVs, and their association with CHD or traditional coronary risk factors can be interpreted as a causal effect of SLE.

The association between genetically predicted SLE and CHD or traditional coronary risk factors attributable to each SNP was accessed with the Wald method, which computes the ratio between the SNP-SLE and SNP-CHD or SNP-traditional coronary risk factors estimates. The ratio estimates for individual SNPs were combined by using the inverse-variance weighted (IVW) meta-analysis method (random-effects). We additionally examined the violation of the MR assumptions through sensitivity analyses, based on the weighted median,



MR-Egger, and weighted mode approaches. CARDIoGRAMplusC4D Consortium was set as the outcome in MR analysis unless there was directional horizontal pleiotropy, when CARDIoGRAM Consortium would replace it. Cochran's Q value was furthermore estimated to measure the heterogeneity in the inverse-variance weighted (IVW) and MR-Egger analysis. If there was significant heterogeneity between SNPs, they would be further analyzed with outlier-corrected MR-PRESSO.

The prevalence of SLE in Caucasians was estimated at 47.5 per 100,000 persons[19]. Effect allele frequencies of SNPs were estimated with SNPsnap[20] using 1000 Genomes data if not available from GWAS. And heritability of liability attributable to each SNP ( $h^2$ ) was estimated with INDI-V[21].

All the above analyses were performed in R, version 3.5.1. Lipid profile in SLE patients was compared with that in controls via unpaired t-test. *P* values were 2-sided, and evidence of association was declared at  $P < 0.05$ .

## **Results**

### **Genetic loci associated with SLE**

The identified risk loci in the three GWAS for SLE explained an estimated 8% -19.3% [22, 23] of the total genetic susceptibility to SLE. We selected SNPs (or LD proxies) from these three GWAS as IVs for SLE risk (Table 1 and Supplementary Table S1). The selected SNPs correspond to independent genomic regions with an odds ratio (OR) from 1.13 to 2.28, and an  $h^2$  from 0.06% to 3.28% for SLE.

### **Associations of genetic risk of SLE with coronary heart disease**

To estimate the effect of genetically raised SLE risk on CHD risk, we used the IVW MR

analysis (random-effects) in which the SLE risk-increasing variants were treated as IVs (Figure 1 and Methods section). A random-effects IVW model yielded a pooled MR estimate of nonsignificant effect, demonstrating that SLE increased the odds of CHD by 1.00 (95% CI, 0.97, 1.04;  $P=0.91$ , Bentham, J. et al.), 1.01 (95% CI, 0.98, 1.04;  $P=0.63$ , Langefeld, C.D. et al.), and 0.98 (95% CI, 0.94, 1.02;  $P=0.24$ , Gateva, V. et al.), respectively (Table 2, Figure 1). Weighted median and weighted mode estimates for the candidate SNPs yielded results similar to those of the random-effects IVW model. We did not find the presence of directional horizontal pleiotropy in any of the three analyses, as indicated by the MR-Egger intercept test ( $P=0.25$ , 0.76, and 0.53, respectively). There was no evidence of heterogeneity in the IVW and MR-Egger analysis with IVs from GWAS by Langefeld, C.D. et al. ( $Q=3.91$ ,  $P=0.56$ ;  $Q=3.81$ ,  $P=0.43$ , respectively) and Gateva, V. et al. ( $Q=5.76$ ,  $P=0.33$ ;  $Q=5.16$ ,  $P=0.27$ , respectively). However, with IVs from GWAS by Bentham J et al., there was significant heterogeneity ( $Q=66.22$ ,  $P<0.001$ ;  $Q=63.36$ ,  $P<0.001$ , respectively), which was further analyzed with outlier-corrected MR-PRESSO (Figure 1).

**Table 2. Two-sample MR estimates for the effect of SLE on CHD risk.**

Genetic instruments	Method	OR (95%CI)	<i>P</i> value	Heterogeneity	Pleiotropy
Bentham, J. et al	MR Egger	0.97 (0.91-1.03)	0.35	<0.001	0.25
	Weighted median	1.00 (0.96-1.04)	0.96		
	Inverse variance	1.00 (0.97-1.04)			
	weighted		0.91	<0.001	
	Weighted mode	1.00 (0.96-1.04)	0.87		
	MR-PRESSO	1.00(0.97-1.03)	0.84		
Langefeld, C.D. et al	MR Egger	1.02 (0.94-1.10)	0.65	0.43	0.76
	Weighted median	0.99 (0.95-1.03)	0.56		

Gateva, V. et al	Inverse variance			0.56	
	weighted	1.01 (0.98-1.04)	0.63		
	Weighted mode	0.98 (0.93-1.04)	0.59		
	MR Egger	0.95 (0.88-1.03)	0.31	0.27	0.53
	Weighted median	0.98 (0.94-1.02)	0.30		
	Inverse variance			0.33	
	weighted	0.98 (0.94-1.02)	0.24		
	Weighted mode	0.98 (0.93-1.03)	0.42		
	OR, odds ratio; Heterogeneity, <i>P</i> value for Cochran's Q test; Pleiotropy, <i>P</i> value for MR-Egger intercept test.				

### Associations of genetic risk of SLE with traditional coronary risk factors

MR analysis (IVW random-effects) indicated that SLE increased the odds of LDL-cholesterol by 0.99 (95% CI, 0.98, 1.01; *P*= 0.33), HDL-cholesterol by 0.99 (95% CI, 0.97, 1.00; *P*= 0.03), apolipoprotein A-I by 0.98 (95% CI, 0.97, 1.00; *P*= 0.01), apolipoprotein B by 0.99 (95% CI, 0.98, 1.01; *P*= 0.39), diabetes mellitus by 1.001 (95% CI, 1.000, 1.001; *P*= 0.27) and hypertension by 1.001 (95% CI, 1.000, 1.002; *P*= 0.23), respectively, without directional horizontal pleiotropy (Figure 1).

### Association between SLE and premature coronary atherosclerosis

A genome-wide scale time-to-event data analysis of UK Biobank data identified 69 risk loci associated with premature coronary atherosclerosis [17]. There was one common risk locus (rs597808-A) between SLE and premature coronary atherosclerosis at a genome-wide significance level ( $P < 5 \times 10^{-8}$ ), which was also associated with decreased HDL and LDL [24].

### Dyslipidemia in treatment-naïve SLE patients

We reviewed the baseline lipid profile before any treatments in 218 SLE patients (198 female/20 male). An age-matched population (45,613 female/49,519 male) were involved as healthy controls. In both sexes, HDL-cholesterol ( $0.98\pm0.516\text{mmol/L}$  vs.  $1.46\pm0.307\text{mmol/L}$  in female,  $0.76\pm0.199\text{mmol/L}$  vs.  $1.19\pm0.257\text{mmol/L}$  in male; both  $P<0.001$ ) and apolipoprotein A-I ( $1.06\pm0.314\text{g/L}$  vs.  $1.37\pm0.205\text{g/L}$  in female,  $0.87\pm0.174\text{g/L}$  vs.  $1.24\pm0.200\text{g/L}$  in male; both  $P<0.001$ ) were significantly decreased in naïve SLE patients. Additionally, LDL-cholesterol, apolipoprotein B, and total cholesterol were decreased as well. Triglyceride level was increased in female SLE patients, but not in male patients (Table 3). The prevalence of CHD, diabetes mellitus, and hypertension in SLE patients was 0.9%, 1.4%, and 11.9%, respectively, which were comparable to or lower than that in the general population in China.

**Table 3. Characteristics and lipid profiles in naïve SLE patients and healthy controls.**

Characteristics		SLE(n=218)(mean±SD)	Controls(n=95,132) (mean±SD)	P value
Female/Male		198/20	45,613/49,519	
Age, years				
	Female	37.5±13.8	37.7±8.9	>0.05
	Male	43.4±19.2	43.7±10.0	>0.05
Coronary Heart Diseases,%		0.9(2/218)	1.02 <sup>#</sup>	
Diabetes Mellitus,%		1.4(3/218)	3.7 <sup>*</sup>	
Hypertension,%		11.9(26/218)	22 <sup>&amp;</sup>	
Total cholesterol, mmol/L				
	Female	3.92±1.111	4.90±0.940	<0.0001
	Male	3.70±0.692	5.05±0.913	<0.0001

HDL, mmol/L				
	Female	0.98±0.516	1.46±0.307	<0.0001
	Male	0.76±0.199	1.19±0.257	<0.0001
LDL, mmol/L				
	Female	2.09±0.766	2.80±0.783	<0.0001
	Male	2.11±0.695	3.01±0.773	<0.0001
Apo A-I, g/L				
	Female	1.06±0.314	1.37±0.205	<0.0001
	Male	0.87±0.174	1.24±0.200	<0.0001
Apo B, g/L				
	Female	0.81±0.248	0.92±0.257	<0.0001
	Male	0.80±0.189	1.03±0.253	<0.0001
Triglyceride, mmol/L				
	Female	1.71±0.891	1.21±0.959	<0.0001
	Male	1.55±0.732	2.02±1.629	<0.0001
HDL, HDL cholesterol; LDL, LDL cholesterol; Apo A-I, Apolipoprotein A-I; Apo B, Apolipoprotein B				

#, estimated from the prevalence of CHD in the general population aged 30-50 years in China [25]; \*, estimated from the prevalence of DM in the general population aged 30-50 years in China [26]; &, estimated from the prevalence of hypertension in the general population aged 35-54 years in China.

## Discussion

Our study did not find a significant causal effect of SLE on CHD, indicating that genetically predicted SLE may not cause coronary heart disease in old patients (>50 years old).

Nevertheless, the secondary analysis showed that SLE had a mild decreasing effect on

HDL-cholesterol and apolipoprotein A-I, which was consistent with previous observational

studies[27] and our real-world data analysis. It may partially explain premature coronary-artery atherosclerosis in young SLE patients[6].

Previous investigations demonstrated an increased risk for CHD in SLE patients, in which both traditional and SLE-specific risk factors are important [8, 11]. However, there are still discrepancies within the literature. Some studies showed similar disease activity in SLE patients with or without coronary-artery calcification, and accelerated plaque progression in SLE regardless of disease activity [6, 10], while others showed SLE disease activity as one of the predictors of CHD [9, 28]. Additionally, previous studies diverged regarding whether atherosclerosis was more common in SLE than in controls, and further subgroup analyses found that lupus nephritis (LN) accelerated atherosclerosis and increased risk for CHD [4, 29].

Because of the existence of several closely associated risk factors, such as disease activity and glucocorticoid use, it is difficult to disentangle their effects [30]. For instance, a recent study compared atherosclerotic comorbidities in corticosteroid-naïve and corticosteroid-exposed patients with SLE, with a minimum of 3 years of follow-up[31]. They found no difference in the frequency of coronary artery disease overall or at each of the time points (3, 5, and 8 years, respectively). However, the corticosteroid-exposed patients had higher Systemic Lupus Erythematosus Disease Activity Index 2000 scores on first examination and more immunosuppressive treatment, which were not balanced between the two groups.

Nevertheless, cumulative corticosteroid dose and disease duration were found to be associated with plaque progression in most of the studies [9, 10]. A recent large matched cohort study showed that the risk for CHD was highest during the first year after SLE diagnosis [32].

Moreover, a long-term prospective study indicated that disease-related factors seemed to dominate CHD risk during the first 8 years, while traditional factors such as hypertension and diabetes, partially related to corticosteroid treatment, played an important role later in the disease course [33]. Notably, increased CHD prevalence in SLE was more common in younger patients rather than in old patients (>50 years old). The association between SLE and CHD was attenuated with increasing age [3].

As a complex trait, CHD would be influenced by lots of factors besides genetics, especially in old patients. As we know, CHD commonly occurred in old patients who were more than 50 years old. However, the onset of SLE was mainly in young females around child-birth age. The age gap may dilute the genetic effect of SLE on CHD. So, despite the null result of our primary analysis, we could not draw the same conclusion in young-onset CHD patients. In contrast, we may get a different result if calculating the effect of IVs for SLE against GWAS of CHD in young patients, as demonstrated by the common risk locus (rs597808-A) between SLE and premature coronary atherosclerosis in the time-to-event data analysis of UK Biobank data. Further analyses are needed to take into account the age gap between the onset of SLE and CHD in the general population.

Besides HDL-cholesterol and apolipoprotein A-I, LDL-cholesterol, apolipoprotein B, and total cholesterol were decreased in naïve SLE patients as well. Rs597808 may partly account for the dyslipidemia in SLE [24, 34]. However, it still needs further investigation to elucidate whether and how the dyslipidemia participated in the premature coronary atherosclerosis in SLE.

The limitations of this study include five parts. First, data of associations of

SNP-exposure and SNP-outcome were derived from 2 different populations, which would increase heterogeneity, as we saw in the SNPs from GWAS by Bentham, J. et al. Second, we included SNPs only those with a genome-wide significance level ( $P < 5 \times 10^{-8}$ ), meaning those genuinely associated variants that did not reach the stringent p-value threshold were ignored. Recently, e.g., a comparative study found that an IL19 risk allele, rs17581834 (T), was associated with stroke/myocardial infarction in SLE (OR 2.3 (1.5 to 3.4),  $P = 8.5 \times 10^{-5}$ ). However, we neither found it in the three GWAS on SLE nor in the CARDIoGRAMplusC4D Consortium dataset due to  $P$ -value. Third, though three GWAS on SLE were all of European ancestry, CARDIoGRAMplusC4D Consortium was of mixed ancestry (92.85% European and 7.15% South Asian). However, the directional horizontal pleiotropic effect was not observed in the MR-Egger regression in this study. Fourth, we may have underestimated the risk of CHD in SLE, since there may be an increased risk for early death from CHD in SLE. Last, the real-world data were from the Chinese population rather than the European population. Despite the difference, the majority of genetic risk polymorphisms for SLE are present in both populations[35], supporting the effectiveness of the analysis.

Though most of the selected SNPs were each estimated to account for less than 1% of the genetic variance, multi-SNPs in combination, i.e., IVs, could explain up to 12% of estimated heritability of liability to SLE in the primary analysis (16.3-17.8% in the secondary analysis). Additionally, we conducted 2-sample MR analyses by using genetic instruments from three large independent GWAS separately in our study, which would strengthen the power of our conclusion.



## Key messages

### What is already known about this subject?

Patients with systemic lupus erythematosus (SLE) has increased risk for coronary heart disease (CHD), which has been the leading cause of hospitalization and in-hospital mortality in patients with SLE. But whether there is a causal relationship between SLE and CHD is uncertain.

Genetic variants related to SLE can be used as proxies for SLE to help judge causality (“Mendelian randomisation analyses”).

Previous studies have been insufficiently powerful and detailed to evaluate the possibility of any causal role for SLE in CHD.

### What does this study add?

SLE may accelerate coronary atherosclerosis in young patients by reducing HDL cholesterol and apolipoprotein A-I intrinsically, but it seems not to play a predominant role in CHD development in old patients.

### How might this impact on clinical practice or future developments?

We should caution the dyslipidemia and premature coronary atherosclerosis in young SLE patients. Treatments for SLE, such as corticosteroid use, should be considered more carefully to decrease CHD risk.

## Author affiliations

<sup>1</sup>Department of Rheumatology and Immunology, the Third Affiliated Hospital of Soochow University, Changzhou 213000, China.

## Acknowledgements

We wish to thank the CARDIOGRAMplusC4D, CARDIOGRAM, MRC-IEU, GWAS by Bentham, J. et al., Langefeld, C.D. et al., Gateva, V. et al., Kettunen, J. et al., and Wenjian, B. et al. for access to their data.

**Funding:** Supported by grants from the Science and Technology Project of Changzhou Health Committee for Young Talents (QN201805).

**Contributors:** The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

**Competing interests:** None declared.

**Ethical approval:** The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Soochow University and individual consent for this retrospective analysis was waived.

**Data Availability Statement** The data underlying this article are available in the NHGRI-EBI GWAS catalog, at <https://www.ebi.ac.uk/gwas/>, and MR Base database, at <http://app.mrbase.org>. The cumulative risk curves of the risk loci for coronary artery atherosclerosis are available at [ftp://share.sph.umich.edu/UKBB\\_SPACox\\_HRC/Survplot](ftp://share.sph.umich.edu/UKBB_SPACox_HRC/Survplot).

## REFERENCES

- 1 Alarcón-Segovia D, Alarcón-Riquelme ME, Cardiel MH, et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from

- the GLADEL cohort. *Arthritis Rheum* 2005;52(4):1138–47.
- 2 Tektonidou MG, Wang Z, Ward MM. Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. *Arthritis Rheumatol* 2016;68(11):2680–85.
- 3 Katz G, Smilowitz NR, Blazer A, et al. Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. *Mayo Clin Proc* 2019;94(8):1436–43.
- 4 Hermansen M-L, Sandholt B, Fuchs A, et al. Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. *Rheumatology (Oxford)* 2018;57(11):1964–71.
- 5 Chazal T, Kerneis M, Guedeney P, et al. Coronary artery disease in systemic lupus: A case-controlled angiographic study. *Autoimmun Rev* 2020;19(1):102427.
- 6 Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med* 2003;349(25):2407–15.
- 7 Barbhuiya M, Feldman CH, Guan H, et al. Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2017;69(9):1823–31.
- 8 Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. United States 2013 Aug.
- 9 Romero-Diaz J, Vargas-Vorackova F, Kimura-Hayama E, et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. *Rheumatology (Oxford)* 2012;51(1):110–19.
- 10 Kravvariti E, Konstantonis G, Sfrikakis PP, et al. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. *Rheumatology (Oxford)* 2018;57(12):2158–66.
- 11 Kiani AN, Magder LS, Post WS, et al. Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. *Rheumatology (Oxford)* 2015;54(11):1976–81.
- 12 Vyse TJ, Todd JA. Genetic Analysis of Autoimmune Disease. *Cell* 1996;85(3). <https://pubmed.ncbi.nlm.nih.gov/8616887/>.
- 13 Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet* 2013;45(1):25–33.
- 14 Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 2011;43(4):333–38.
- 15 Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 2014;42(Database issue):D1001–6.
- 16 Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenotype. *Elife* 2018;7.
- 17 Bi W, Fritsche LG, Mukherjee B, et al. A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank. *American journal of human genetics* 2020;107(2). <https://pubmed.ncbi.nlm.nih.gov/32589924/>.
- 18 Haycock PC, Burgess S, Wade KH, et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J Clin Nutr* 2016;103(4):965–78.
- 19 Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. *Arthritis Rheumatol* 2014;66(2):369–78.
- 20 Pers TH, Timshel P, Hirschhorn JN. SNPsnap: a Web-based tool for identification and annotation of

- matched SNPs. *Bioinformatics* 2015;31(3):418–20.
- 21 Witte JS, Visscher PM, Wray NR. The contribution of genetic variants to disease depends on the ruler. *Nat Rev Genet* 2014;15(11):765–76.
- 22 Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* 2009;41(11):1228–33.
- 23 Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat Genet* 2015;47(12):1457–64.
- 24 Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;45(11):1274–83.
- 25 Wang Y, Li Y, Liu X, et al. Prevalence and Influencing Factors of Coronary Heart Disease and Stroke in Chinese Rural Adults: The Henan Rural Cohort Study. *Front. Public Health* 001;0:411. <https://www.frontiersin.org/articles/10.3389/fpubh.2019.00411/full>.
- 26 Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. *BMJ (Clinical research ed.)* 2020;369. <https://pubmed.ncbi.nlm.nih.gov/32345662/>.
- 27 Kim SY, Yu M, Morin EE, et al. High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. *Arthritis Rheumatol* 2020;72(1). <https://pubmed.ncbi.nlm.nih.gov/31350818/>.
- 28 Recio-Mayoral A, Mason JC, Kaski JC, et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. *Eur Heart J* 2009;30(15):1837–43.
- 29 Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, et al. Excess atherosclerosis in systemic lupus erythematosus, -A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. *PLoS ONE* 2017;12(4):e0174572.
- 30 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. *Eur Heart J* 2015;36(8):482-9c.
- 31 Sheane BJ, Gladman DD, Su J, et al. Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)* 2017;69(2). <https://pubmed.ncbi.nlm.nih.gov/27214378/>.
- 32 Aviña-Zubieta JA, To F, Vostretsova K, et al. Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. *Arthritis Care Res (Hoboken)* 2017;69(6):849–56.
- 33 Tselios K, Gladman DD, Su J, et al. Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. *J Rheumatol* 2017;44(12):1841–49.
- 34 Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. *PLoS medicine* 2020;17(3). <https://pubmed.ncbi.nlm.nih.gov/32203549/>.
- 35 Morris DL, Sheng Y, Zhang Y, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. *Nat Genet* 2016;48(8). <https://pubmed.ncbi.nlm.nih.gov/27399966/>.

**Figure 1. Associations between genetically increased SLE risk and odds of CHD or traditional risk factors for CHD.**

Mendelian randomization analyses of the causal relationship between SLE and CHD or traditional risk factors for CHD in the inverse-variance weighted model.

SNPs, single nucleotide polymorphisms;  $h^2$ , heritability of liability attributable to this risk variant by the approximate equation;

OR, odds ratio.

*P* value-a, *P*-value for the association between genetically increased SLE risk and diseases from IVW meta-analysis (random-effects).

*P* value-b, *P* value for horizontal Pleiotropy from MR-Egger intercept test.

*P* value-c, *P* value for heterogeneity among SNPs within the instrument from Cochran's Q test.



